Clinical Trial Update: Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) [Phase 3]

View source ↗

Summary

Phase 3 trial of acoramidis (AG10) for transthyretin-related familial amyloid polyneuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-related Familial Amyloid Polyneuropathy

Drugs mentioned

• Acoramidis (AG10) (acoramidis)

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Phase 3 | Status: WITHDRAWN